TITLE

2011 - Review: Rosiglitazone increases risk for cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes

AUTHOR(S)
Deedwania, Prakash
PUB. DATE
August 2011
SOURCE
ACP Journal Club;8/16/2011, Vol. 155 Issue 2, p11
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a study by Loke Y. K. and colleagues focusing on how rosiglitazone increased the risk for cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes. The study showed that rosiglitazone was associated with adverse cardiovascular (CV) outcomes including myocardial infarction (MI), congestive heart failure, and overall mortality.
ACCESSION #
65456928

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics